Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease (AFF011)

• ClinicalTrials.gov Identifier: NCT02267434
• Recruitment Status: Completed
• First Posted: October 17, 2014
• Last Update Posted: October 31, 2016
• Sponsor: Affiris AG
• Collaborators: PROSENEX AmbulatoriumbetriebsGMBH; Medical University Innsbruck; Forschungszentrum Juelich
• Information provided by (Responsible Party): Affiris AG

Study Description

Brief Summary:

Study AFF011 is a randomized controlled parallel Group phase I study to investigate the safety and tolerability of two doses of the vaccine AFFITOPE® PD03A given to patients with early Parkinson's disease.

In total 36 patients will be enrolled in 3 independent groups (2 treatment groups, 1 Placebo group), each consisting of 12 patients. The patients will be randomized to either receive 15µg or 75µg AFFITOPE® PD03A formulated with adjuvant or the reference substance without active component (Placebo). Over a study duration of 52 weeks, the study participants receive 4 injections as basic immunization in a 4-weekly interval and 1 boost immunization 36 weeks after the first injection. Male and female patients aged 45 to 70 years can participate in the trial. 2 study sites in Austria (Innsbruck and Vienna) will be involved.

AFF011 is part of a project SYMPATH funded by the European Commission (FP7-HEALTH-2013-INNOVATION-1 project; N° HEALTH-F4-2013-602999).

Condition or disease	Intervention/treatment	Phase
Parkinson Disease; Neurodegenerative Diseases	Biological: Low dose AFFITOPE® PD03A + Adjuvant; Biological: High dose AFFITOPE® PD03A + Adjuvant; Biological: Adjuvant without active component	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 36 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Primary Purpose: Treatment
• Official Title: A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease
• Study Start Date: December 2014
• Actual Primary Completion Date: August 2016
• Actual Study Completion Date: August 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Low dose AFFITOPE® PD03A + Adjuvant; 4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks 1 boost immunization 36 weeks after first injection	Biological: Low dose AFFITOPE® PD03A + Adjuvant; s.c. injection
Experimental: High dose AFFITOPE® PD03A + Adjuvant; 4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks 1 boost immunization 36 weeks after first injection	Biological: High dose AFFITOPE® PD03A + Adjuvant; s.c. injection
Placebo Comparator: Adjuvant without active component; 4 injections of Placebo once every 4 weeks 1 administration 36 weeks after first injection	Biological: Adjuvant without active component; s.c. injection

Outcome Measures

Primary Outcome Measures :

1. Number of patients who withdraw due to Adverse Events (AEs) [ Time Frame: 12 months ]
   The withdrawal criteria (continuation decision) in regards to the number of patients who withdraw due to AEs as well as the reason for withdrawal will be evaluated.
2. Occurrence of Adverse Events and Serious Adverse Events [ Time Frame: 12 months ]
   Evaluation of Adverse Events and Serious Adverse Events in regards to autoimmune reactions
3. New findings or Change in pre-existing findings assessed in physical and neurological examinations over time (study period) [ Time Frame: 12 months ]
4. Change in vital signs and Body mass over time (study period) [ Time Frame: 12 months ]
   The Evaluation of vital signs includes the changes in blood pressure, heart rate, respiratory rate and Body temperature over time (measured at each visit).
5. Safety related Evaluation of MRI results of patients' brain after visit 5 and visit 8 compared to baseline [ Time Frame: 12 months ]
   MRI safety measures will e.g. include the occurrence of inflammatory reactions (meningoencephalitis), new/changed hemorrhages and lacunar infarcts.
6. Clinical significance/changes in laboratory parameters over time (study period) [ Time Frame: 12 months ]
   Laboratory assessment includes hematology, biochemistry, coagulation, serology and urinanalysis.

Secondary Outcome Measures :

1. Immunological activity of AFFITOPE® vaccine PD03A [ Time Frame: 12 months ]
   Titer of vaccination induced antibodies directed towards vaccine components, alpha- and beta synuclein
2. Change in motor symptoms at visit 8 and visit 11 compared to baseline [ Time Frame: 12 months ]
   Change in motor symptoms: MDS Unified Parkinson's Disease Rating Scale (UPDRS) II and III
3. Change in non-motor symptoms at visit 8 and visit 11 compared to baseline [ Time Frame: 12 months ]
   Change in non-motor symptoms: PDQ-39 (Parkinson's Disease Quality of Life-39)/PD non-motor symptom score, MDS UPDRS I (Movement Disorder Society Unified Parkinson's Disease Rating scale), cognitive test battery, HAM-D (Hamilton Depression Rating Scale)

Eligibility Criteria

• Ages Eligible for Study: 45 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Individuals with IPS diagnosed for less than 4 years and who present in Hoehn & Yahr Stages I/II and fulfill the United Kingdom Parkinson's Disease Society Brain Bank Criteria
• The result of a DAT-SPECT and MRI examination of the patient's brain has to be consistent with the diagnosis of PD
• Written Informed Consent Form signed and dated by the patient
• Age between 45 and 70
• Female patients of childbearing potential are eligible if they use a medically accepted contraceptive method
• A potential participant treated with conventional PD therapies must be on stable doses for at least 3 months prior to Visit 0 and during the entire trial period and must be a stable responder
• Accepted PD medications include the following: levodopa (alone or in combination with benserazide, carbidopa), Catechol-O-methyltransferase inhibitors (entacapone, tolcapone), amantadine, non-ergot dopamine agonists (pramipexol, ropinirol, rotigotine), monoamine oxidase-B inhibitors (rasagiline, selegiline) and anticholinergic medication
• A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except PD therapies, these will be recorded separately) for at least 30 days prior to Visit 0, if considered relevant by the PI
• Upon PI's opinion, no visual or auditory impairments that would reduce the patients' ability to complete study questionnaires or be unable to receive instructions for these

Exclusion Criteria:

• Pregnant women
• Sexually active women of childbearing potential who are not using a medically accepted birth control method throughout the study
• Participation in another clinical trial within 3 months before Visit 0
• History of questionable compliance to visit schedule; patients not expected to complete the clinical trial
• Presence or history of allergy to components of the vaccine, if considered relevant by the PI
• Contraindication for MRI imaging such as metallic endoprosthesis or stent implantation in the last 6 months or allergy to MRI contrast agent
• Contraindication for DAT-SPECT
• Contraindication for lumbar puncture such as anticoagulation
• Dementia
• History and/or presence of autoimmune disease, if considered relevant by the PI
• Recent (≤3 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia)
• Active infectious disease (e.g., Hepatitis B, C)
• Presence and/or history of Immunodeficiency (e.g., HIV)
• Significant systemic illness (e.g., chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, other deficiencies), if considered relevant by the PI
• History of significant psychiatric illness such as schizophrenia, bipolar affective disorder or psychotic depression
• Parkinson-like disease secondary to drug therapy side effects (e.g., due to exposure to medications that deplete dopamine [reserpine, tetrabenazine] or block dopamine receptors [neuroleptics, antiemetics]
• Parkinson-plus syndromes (e.g. MSA, PSP)
• Heredodegenerative disorders
• Alcoholism or substance abuse within the past year (alcohol or drug intoxication)
• Prior and/or current treatment with experimental immunotherapeutics including intravenous immunoglobulin
• Prior and/or current treatment with immunosuppressive drugs
• Change in dose of standard treatments for PD within 3 months prior to Visit 0
• Change in dose of previous and current medications which the patient is taking because of consisting illnesses according medical history (except PD therapies, these will be recorded separately) within the last 30 days prior to Visit 0, if clinically relevant
• Treatment with deep brain stimulation
• Venous status rendering it impossible to place an i.v. access
• L-Dopa related motor complications (response fluctuations and/or dyskinesia)
• Evidence for genetic forms of PD: leucine-rich repeat kinase 2 and Parkin

Contacts and Locations

Locations

Austria

Medical University Innsbruck, Department of Neurology

Innsbruck, Austria, 6020

Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität -Privatklinik Josefstadt

Vienna, Austria, 1080

Sponsors and Collaborators

Affiris AG

PROSENEX AmbulatoriumbetriebsGMBH

Medical University Innsbruck

Forschungszentrum Juelich

Investigators

• Principal Investigator: Werner Poewe, MD; Medical University Innsbruck, Department of Neurology, Innsbruck 6020, Austria

More Information

• Responsible Party: Affiris AG
• ClinicalTrials.gov Identifier: NCT02267434
• Other Study ID Numbers: AFFiRiS 011; 2014-000568-16 ( EudraCT Number )
• First Posted: October 17, 2014
• Last Update Posted: October 31, 2016
• Last Verified: October 2016

Additional relevant MeSH terms:

Parkinson Disease; Neurodegenerative Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies